Renal fibrosis represents the final common pathway for nearly all forms of progressive chronic kidney disease (CKD). It is characterized by the excessive accumulation of extracellular matrix (ECM) components, which replaces functional parenchyma with non-functional scar tissue, eventually leading to end-stage renal failure. While the initial triggers vary—ranging from diabetes to acute injury—the progression toward fibrosis often converges on a shared set of molecular signaling pathways.
The TGF-β/Smad Signaling Axis
The most prominent driver of renal fibrosis is the Transforming Growth Factor-beta 1 (TGF-β1) pathway. When the kidney is injured, TGF-β1 levels rise, activating Smad proteins that translocate to the nucleus to trigger the transcription of pro-fibrotic genes.
Research has identified several specific regulators that amplify or dampen this signal. Yao et al. identified the protein P311 as a key promoter of this process; its presence activates the TGF-β1/Smad pathway, accelerating the transition to irreversible scarring. Conversely, certain microRNAs act as natural "brakes" on this system. Qin et al. demonstrated that TGF-β/Smad3 signaling actively inhibits miR-29, a microRNA that normally prevents fibrosis. By restoring miR-29 levels, the authors were able to prevent and even reverse fibrosis in experimental models.
Post-Translational and Epigenetic Regulation
Beyond direct gene transcription, the stability and activity of fibrotic receptors are governed by post-translational modifications. Cui et al. found that the protein ISG15 worsens the transition from acute kidney injury (AKI) to CKD by promoting the "ISGylation" of the TGF-β receptor 1 (TGFβR1). This modification stabilizes the receptor, making the cell hypersensitive to pro-fibrotic signals.
Similarly, the silencing of specific genes via other microRNAs offers therapeutic potential. Wang et al. showed that Emodin, a compound derived from rhubarb, boosts miR-490-3p, which in turn silences HMGA2, a gene that otherwise drives the progression of CKD.
Metabolic Homeostasis and Structural Signaling
Fibrosis is not merely a transcriptional event but is deeply tied to the metabolic health of renal cells. Liu and Xu identified a marine-derived molecule, PA-S14, that activates LKB1, a master metabolic regulator. By restoring autophagy (the cell's internal cleaning mechanism) and mitochondrial homeostasis, this activation helps renal tubular epithelial cells resist fibrotic transformation.
Structural signaling proteins also play a role in maintaining the fibrotic state. Hu et al. discovered that targeting Cdc42—a protein involved in cell structure and signaling—leads to the degradation of β-catenin, a key mediator of fibrotic gene expression. By inhibiting this Cdc42-mediated pathway, the natural molecule daphnepedunin A was shown to mitigate kidney scarring.
Multi-Target Interventions via Natural Products
Given the complexity of these pathways, researchers are increasingly looking toward multi-component therapies that can hit several targets simultaneously. Traditional Chinese medicine formulas and their derivatives have shown promise in this regard:
- DXXK and Scutellaria: Zhang et al. used network pharmacology to show that the formula DXXK suppresses the TGF-β1/Smad2/3 axis. Similarly, a specific mixture of flavonoids from Scutellaria baicalensis was found to be more effective than individual components in restoring kidney function, as reported in Frontiers in Pharmacology (2024).
- Gut-Liver-Kidney Axis: The systemic nature of fibrosis is highlighted by Li et al., who found that Scutellarin alleviates liver fibrosis not just by inhibiting PI3K/AKT signaling, but also by rebalancing the gut microbiome.
- Inflammation and Ferroptosis: Ha et al. demonstrated that Butyrolactone I prevents the AKI-to-CKD transition by targeting JAK1, thereby reducing inflammation and ferroptosis (a form of iron-dependent cell death).
These diverse mechanisms—from microRNA regulation to metabolic restoration—suggest that the most effective future treatments for renal fibrosis will likely involve combination therapies that address both the signaling triggers and the underlying cellular environment.
Key Foundational Work
P311 promotes renal fibrosis via TGFβ1/Smad signaling (2015) — contributed 1 concept elements to this direction.
TGF-β/Smad3 Signaling Promotes Renal Fibrosis by Inhibiting miR-29 (2011) — contributed 1 concept elements to this direction.